Original from: genomeweb

Circular Genomics announced Monday that it raised $15 million in a Series A financing round led by Mountain Group Partners. 

The funds will support the development and commercialization of the San Diego-based, University of New Mexico spinout's circular RNA (circRNA) biomarker platform for the early detection of Alzheimer's disease. 

Together with academic collaborators at Washington University, the company identified a circRNA-based Alzheimer's signature headlined by a circRNA named circHOMER1.

Circular Genomics also intends to use the funding to expand beyond Alzheimer's into other neurodegenerative and psychiatric disorders; pursue collaborations with other academic institutions, pharmaceutical companies, and diagnostic service providers; and continue to hire more personnel.

Other investors in the financing round included Poplar Grove Investors, HIP Fund, and the Alzheimer's Drug Discovery Foundation (ADDF).

"This Series A financing represents a pivotal milestone in our journey to transform precision neurology, including Alzheimer's disease diagnosis and patient care," Circular Genomics CEO Paul Sargeant said in a statement. "With this capital, we are positioned to advance our clinical programs, expand our world-class team, and bring our first transformative test in Alzheimer's disease to patients and physicians who desperately need better diagnostic tools."

Source from: Circular Genomics Closes $15M Series A Round